What is MedMira Inc?
, a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally.
MMIRF · Verdict
Limited reward · high risk
MMIRF's standout is volatility; cash flow and profitability weigh on the picture.
Based on 88% data coverage
MMIRF · Verdict
Above average
-1311% free-cash-flow margin
-1881% net margin · 0% ROE
Current ratio 0.10
Rev -36.8% CAGR · earnings +35.2%
Model-based scoring. For information only — not financial advice.
, a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.28M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.